GIP and Insulin resistance: This suggests that from a clinical classification perspective, muscle and hepatic IR might be combined into one group classified as ‘insulin resistant’, and therapies known to improve insulin resistance (such as dietary or pharmacologic weight loss (including GLP-1 or dual GLP-1/GIP agonists), physical activity, metformin, thiazolidinediones) could be used as initial treatment.